ProMetic to Develop Synthetic Affinity Ligand for Novartis' Vaccine Program | GenomeWeb
NEW YORK (GenomeWeb News) — Synthetic protein drug developer ProMetic Biosciences will develop a synthetic ligand affinity for Novartis, the company said today.
 
PBL, a subsidiary of ProMetic Life Sciences, said Novartis Vaccines has hired it to screen chemical libraries for ligands that may be used to purify a new vaccine product Novartis currently has in clinical trials.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.